Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Valkyrie Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$8,834,133

2,979 payments

Through program year 2025, Valkyrie Clinical Trials is reported as receiving $8,834,133 in research payments, across 2,979 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $5,658,775 1,854
2024 Research $2,906,354 896
2023 Research $201,424 170
2022 Research $67,579 59

Breakdown

Who paid Research payments · program years 2022–2025
  1. Daiichi Sankyo Inc. $2,822,746 1,289 payments
  2. Boehringer Ingelheim International GmbH $2,405,599 353 payments
  3. Incyte Corporation $2,173,707 1,209 payments
  4. Boehringer Ingelheim Pharma GmbH & Co.KG $1,293,032 91 payments
  5. Pfizer Inc. $83,102 6 payments
  6. AbbVie, Inc. $30,475 1 payment
  7. Novartis Pharmaceuticals Corporation $19,979 2 payments
  8. Amgen Inc. $3,052 1 payment
  9. Boehringer Ingelheim Espana S.A. $2,441 27 payments
Studies the money was for Research payments · program years 2022–2025
  1. Ds7300-203 $1,662,609 548 payments
  2. Phase 1 dose escalation study of BI 765049 mono / combi $1,023,296 3 payments
  3. Ds3201-324 $912,216 433 payments
  4. A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors $802,253 238 payments
  5. A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. $783,102 83 payments
  6. Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations $762,559 37 payments
  7. A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors $492,015 400 payments
  8. Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) $441,006 202 payments
  9. Phase Ib/II study in HER2+ amp/overexp mBC and mGC/GEJC $330,618 3 payments
  10. Ds3201-330 $237,652 203 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record